Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.PMID:37290035 | DOI:10.1200/JCO.23.00233

Source: Clinical Prostate Cancer - June 8, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Se Hoon Park Jeffrey C Goh Sang Joon Shin Jae Lyun Lee Niven Mehra Ray McDermott N úria Sala-Gonzalez Peter C Fong Richard Greil Margitta Retz Juan Pablo Sade Patricio Yanez Yi-Hsiu Huang Stephen D Begbie Rustem Airatovich Gafanov Source Type: research